ALKERMES | ALKS - Capitale Ordinario





Capitale Ordinario Cambiamento Data
AbbVie USD 1.77B 608K 2026-06
Acadia Pharmaceuticals USD 172.31M 174K 2026-09
ALKERMES USD 168.03M 489K 2026-09
Amgen USD 541M 0 2026-09
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.68M 141K 2026-09
Bristol-Myers Squibb USD 2.04B 7M 2026-06
Coherus Biosciences USD 121.16M 4.92M 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Ionis Pharmaceuticals USD 166.41M 773K 2026-09
J&J USD 2.41B 1.64M 2026-06
Malin Corporation EUR 200K 0 2024-12
Merck USD 2.47B 1.05M 2026-06
Minerva Neurosciences USD 1000 0 2024-09
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 101.3M 750K 2026-09
Otsuka Holdings JPY 523.91M 1.48M 2026-09
Ovoca Bio EUR 29.49M 0 2025-12
Pfizer USD 5.7B 1000K 2026-09
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Vertex Pharmaceuticals USD 253.5M 200K 2026-09